eCOA: Afterthought Or Essential Strategy? An Expert's View On Choosing And Developing An eCOA Strategy

Clinical trials have long faced challenges in data collection and patient reporting, areas ripe for innovation. The introduction of electronic Clinical Outcome Assessments (eCOA) promised to revolutionize these processes, yet the industry is still grappling with a fundamental question: Is eCOA merely an afterthought, or should it be a core strategy in clinical trials?

In a recent LinkedIn Live discussion, Derk Arts, CEO of Castor, and Joe Dustin, VP at Biofourmis, explored this issue, arguing that the era of custom eCOA solutions may be nearing its end. They advocated for a shift towards a standardized approach to eCOA implementation, particularly for organizations in life sciences that do not typically have specialized ePRO/eCOA teams. This conversation is crucial for those looking to streamline operations and enhance the effectiveness of clinical trials in a rapidly evolving landscape.